EMBL Australia

We’re hiring a Chief Operating Officer to lead the EMBL Australia Secretariat & collaborate closely with the EMBL Australia Council Chair and Scientific Director.

EMBL Australia group leader Professor Max Cryle was part of an international team that reconstructed ancestral antibiotics to learn more about how they work in order to produce new antibiotics to combat the growing threat of antimicrobial resistance. Published in Nature Communications, this vital information will inform the development of next-generation superbug treatments.

EMBL Australia group leader Mikaël Martino has co-founded protein-engineering company Orio Therapeutics.

On a recent visit to EMBL Heidelberg, Ian Smith, Chair of the EMBL Australia Council, spoke about the synergies between EMBL and EMBL Australia, opportunities for collaboration and ideas for exciting future programs.

Michelle Boyle – an EMBL Australia group leader and Snow Medical Fellow based at the Burnet Institute – and Burnet Institute CEO and Director Brendan Crabb share their thoughts on the malaria vaccine newly recommended by the World Health Organisation in an article for The Conversation.

EMBL Australia group leaders Associate Professor Richard Morris, Associate Professor Yann Gambin & Dr Qi Zhang have each been awarded Discovery Project grants, totalling almost $1.7m collectively.

Dr Qi Zhang will commence in December as the first EMBL Australia Group Leader to be based at the South Australian immunoGENomics Cancer Institute (SAiGENCI), Adelaide.

A study co-led by group leader Dr Senthil Arumugam and published in Nature Communications reveals a novel mechanism by which cells control the orderly & timely delivery of molecular cargo.

We’re excited to announce that Dr Qi Zhang will be the first EMBL Australia group leader to be hosted at the South Australian immunoGENomics Cancer Institute.

EMBL Australia researchers have made an exciting breakthrough in the field of regenerative medicine, offering new hope for safer and more effective treatments.